Despite being recognized as one of the most common types of pain, few drugs have gained a specific indication for postoperative pain. With most patients still receiving inadequate postoperative pain relief, there is a significant opportunity for manufacturers of drugs with improved side effect profiles or novel compounds, such as Pfizer’s Dynastat, to move into the postoperative pain market.

Scope

> Overview of epidemiology and potential market size for the treatment of postoperative pain

> Examination of current clinical practice including professional involvement, clinical guidelines, and treatment strategies

> Assessment of key unmet needs in the postoperative pain treatment.

> Evaluation of the therapeutic potential for key products currently in development 

Report Highlights

> Postoperative pain affects up to 53m patients in the US alone. Despite most patients receiving some form of pain management, over half of these patients still experience inadequate pain relief. Improved patient and physician education is key to improving treatment outcomes

> Opioids and traditional NSAIDs are the mainstay of postoperative pain treatment. However, compounds such as Pfizer’s Dynastat, which demonstrate equivalent efficacy but fewer side effects, are desperately needed. As a result, new compounds boasting novel modes of delivery will drive patient segmentation in this developing market. 

Reasons to Purchase

> Assess leading drugs used for postoperative pain and understand key success factors within this market

> Identify key unmet needs and pinpoint areas of the market that are not being fully exploited by competitors

> Benchmark pipeline products against currently marketed products and assess future market potential 

April 2004 Pages: 45 

Publisher: Datamonitor CNS Central Nervous System 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS_Central_Nervous_System_2004.html#a599